Menu
Home
Specialties
Services
Contact Janssen
Menu
Specialties
Services
Contact Janssen
Interesting Links
AMY DA site - i can understand - tab Improved awareness journey - video 1 inside fragment
Services
Media Center
It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
Chapters
00:00:15
Diagnosing AL amyloidosis early,
00:00:18
it relies on increasing awareness.
00:00:22
Once you have unexplained nephrotic syndrome
00:00:25
unexplained congestive heart failure, unintentional weight loss,
00:00:29
peripheral and autonomic neuropathy, and even acquired Factor X deficiency
00:00:35
leading to coagulopathy, the suspicion
00:00:39
for AL amyloidosis should be high.
00:00:47
The therapeutic landscape for systemic AL amyloidosis
00:00:51
has changed and expanded dramatically
00:00:55
in the last 20 years, and that is the span of my career.
00:01:00
So the treatments are twofold.
00:01:01
The first is the definitive treatment
00:01:04
attacking the plasma cell dyscrasia
00:01:07
and the second treatment is the supportive treatment
00:01:10
is based on expertise from subspecialties
00:01:15
to make patients’ quality of life better
00:01:19
by controlling congestive heart failure
00:01:22
and nephrotic syndrome and autonomic neuropathy.
00:01:26
But the treatments that are directed towards
00:01:29
the plasma cell dyscrasia reduces the production
00:01:32
of the amyloidogenic light chains to improve the organ dysfunction
00:01:37
and, hence, improve the outlook and prognosis of patients with AL amyloidosis.
00:01:44
Even before you start treatment,
00:01:46
multidisciplinary collaboration is key in figuring out
00:01:50
if a patient is a candidate for aggressive treatment.
00:01:55
And I think—we do this every Friday at the Amyloidosis Center
00:01:58
here where we sit down, and we discuss every patient.
00:02:00
And Dr. Sanchorawala will ask us as cardiologists
00:02:05
do you think this patient can tolerate the treatment that I’m thinking of?
00:02:08
Do you think this patient can tolerate
00:02:10
aggressive treatment because of their heart involvement?
00:02:13
So, I think the cardiologist takes a really important role
00:02:16
in figuring out if a patient is a candidate
00:02:19
for aggressive anti-plasma cell treatment
00:02:21
or for modifying that treatment
00:02:24
so that they are candidates for treatment.
00:02:32
I’m sort of really impressed by how far we’ve come in this field,
00:02:34
and I think that there is real promise
00:02:37
to take this disease that used to be uniformly fatal
00:02:41
and convert it into more of a chronic disease that we can manage.
00:02:46
Really the next step in this treatment, in this disease,
00:02:48
is to figure out how to prevent
00:02:50
progression of the organs that are involved.
00:02:53
Remember, that you're working on 2 levels here.
00:02:56
You're working at the level of a plasma cell dyscrasia
00:02:59
for bone marrow disorder, but then, this
00:03:02
amyloid protein is depositing in organs and causing organ failure,
00:03:05
heart failure, kidney failure, nervous system problems, GI problems.
00:03:10
I think that’s really where the future is,
00:03:11
and there's a lot of interesting developing things like that
00:03:14
when somebody develops signs of organ damage,
00:03:17
you know, how do you reverse that?
00:03:19
And I think that is going to be the next frontier for us.